Boya Bio-Pharmaceutical's 2024 AGM passes key resolutions

Boya Bio-Pharmaceutical Group Co., Ltd. successfully held its 2024 Annual General Meeting (AGM) on April 10, 2025, at its facility in Fuzhou. Legal counsel, Dentons, affirmed the meeting's compliance with relevant laws and regulations. Key resolutions passed include the approval of director and executive compensation for 2024, the addition of non-independent directors, the 2024 Board and Supervisory Board work reports, the 2024 annual report, and the 2024 financial statements and 2025 budget. Shareholders also approved the 2024 profit distribution plan, the estimated 2025 related-party transaction limits, the reappointment of the audit firm for 2025, and amendments to the company's articles of association and the selection process for accounting firms. The meeting was attended by shareholders representing a total of 197,936,000+ shares, combining on-site and online voting, with votes cast in accordance with applicable legal and regulatory requirements.